NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
16 févr. 2024 10h40 HE
|
Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
14 févr. 2024 07h53 HE
|
ZyVersa Therapeutics
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
Durin Technologies Receives Additional Funding to Accelerate Growth
05 déc. 2023 10h00 HE
|
Durin Technologies
Stratford, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Durin Technologies, Inc., an innovator in neurodegenerative disease diagnostic test development and commercialization, today announced funding of...
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
04 déc. 2023 16h35 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
04 déc. 2023 08h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of...
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
04 déc. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
29 nov. 2023 08h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
14 nov. 2023 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
09 nov. 2023 08h30 HE
|
PHARMA TWO B LTD
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and dopaminergic side effects...